Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 22, 2005, Pages 5095-5099

  Swahn, Britt Marie ^a   Huerta, Fernando ^a   Kallin, Elisabet ^a   Malmström, Jonas ^a   Weigelt, Tatjana ^a   Viklund, Jenny ^a   Womack, Patrick ^a   Xue, Yafeng ^b   Öhberg, Liselotte ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

6 Anilinoindazoles; c Jun N terminal kinase 3; JNK3 inhibitors; Structure based design

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; INDAZOLE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG SYNTHESIS; ENZYME INHIBITION; SUBSTITUTION REACTION; X RAY ANALYSIS;

EID: 25844464801     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.06.083     Document Type: Article

References (30)

1. S. Gupta, T. Barrett, A.J. Whitmarsh, J. Cavanagh, H.K. Sluss, B. Derijard, and R.J. Davis EMBO J. 15 1996 2760
2. A.A. Mohit, J.H. Martin, and C.A. Miller Neuron 14 1995 67
3. D.D. Yang, C.-Y. Kuan, M.R. Whitmarsh, T.S. Zheng, R.J. Davis, P. Rakic, and R.A. Flavell Nature 389 1997 865
4. C.Y. Kuan, A.J. Whitmarsh, D.D. Yang, G.H. Liao, A.J. Schloemer, C. Dong, J. Bao, K.J. Banasiak, G.G. Haddad, R.A. Flavell, R.J. Davis, and P. Rakic PNAS 100 2003 15184
5. S. Hunot, M. Vila, P. Teismann, R.J. Davis, E.C. Hirsch, S. Przedborski, P. Rakic, and R.A. Flavell PNAS 101 2004 665
6. L.F. Chang, Y. Jones, M.H. Ellisman, L.S.B. Goldstein, and M. Karin Dev. Cell 4 2003 521
7. C.Y. Kuan, D.D. Yang, D.R.S. Roy, R.J. Davis, P. Rakic, and R.A. Flavell Neuron 22 1999 667
8. T. Ruckle, M. Biamonte, T. Grippi-Vallotton, S. Arkinstall, Y. Cambet, M. Camps, C. Chabert, D.J. Church, S. Halazy, X. Jiang, I. Martinou, A. Nichols, W. Sauer, and J.-P. Gotteland J. Med. Chem. 47 2004 6921
9. G. Scapin, S.B. Patel, J.-M. Lisnock, J.W. Becker, and P.V. LoGrasso Chem. Biol. 10 2003 705
10. Y.-S. Heo, S.-K. Kim, C.I. Seo, Y.K. Kim, B.-J. Sung, H.S. Lee, J.I. Lee, S.-Y. Park, J.H. Kim, K.Y. Hwang, Y.-L. Hyun, Y.H. Jeon, S. Ro, J.M. Cho, T.G. Lee, and C.-H. Yang EMBO 23 2004 2185
11. X. Xie, Y. Gu, T. Fox, J.T. Coll, M.A. Fleming, W. Markland, P.R. Caron, K.P. Wilson, and M.S. Su Structure 6 1998 983
12. T.F. Gallagher, G.L. Seibel, S. Kassis, J.T. Laydon, M.J. Blumenthal, J.C. Lee, D. Lee, J.C. Boehm, S.M. Fier-Thompson, J.W. Abt, M.E. Soreson, J.M. Smietana, R.F. Hall, R.S. Garigipati, P.E. Bender, K.F. Erhard, A.J. Krog, G.A. Hofmann, P.L. Sheldrake, P.C. McDonnell, S. Kumar, P.R. Young, and J.L. Adams Bioorg. Med. Chem. 5 1997 49
13. K.P. Wilson, P.G. McCaffrey, K. Hsiao, S. Pazhanisamy, V. Galullo, G.W. Bemis, M. Fitzgibbon, P. Caron, M.M. Murcko, and M.S. Su Chem. Biol. 4 1997 423
14. The expression, crystallization and structure work on JNK1 and JNK3 will be published elsewhere (Xue, Y.; Geschwinder, G.).
15. As part of a JNK3 inhibitor program, the AstraZeneca compound collection was screened in a scintillation proximity assay-based HTS that employed human recombinant JNK3 and a biotin tagged ATF-2. The activities & potencies of hits were subsequently confirmed in a conventional filter wash assay. For specific conditions see King, S.; Teague, S.; Xue, Y.; Swahn, B.-M. WO2003051277, 2003; Chem. Abstr. 2003, 139, 53019.
16. Figures 1, 3, 4 and 5 were generated using PyMOL, Ref.: W.L. DeLano The PyMOL Molecular Graphics System 2002 DeLano Scientific San Carlos, CA, USA
17. All structures were overlaid by using the program MAPS, ref: Guoguang Lu, An automatic topological and atomic comparison program for protein structures (in manuscript).
18. M.J. Stocks, S. Barber, R. Ford, F. Leroux, S. St-Gallay, S. Teague, and Y. Xue Bioorg. Med. Chem. Lett. 15 2005 3459
19. Malmström, J.; Swahn, B.-M. WO2003068754, Chem. Abstr. 2003, 139, 197477.
20. V. Collot, P. Dallemagne, P.R. Bovy, and S. Rault Tetrahedron 55 1999 6917
21. V. Collot, P.R. Bovy, and S. Rault Tetrahedron Lett. 41 2000 4363
22. For reviews of the Suzuki reaction, see A.J. Suzuki Organomet. Chem. 653 2002 83
23. A.J. Suzuki Organomet. Chem. 576 1999 147
24. N. Miyaura, and A. Suzuki Chem. Rev. 95 1995 2457
25. J.P. Wolfe, and S.L. Buchwald J. Org. Chem. 65 2000 1144
26. J.P. Wolfe, S. Wagaw, J.-F. Marcoux, and S.L. Buchwald Acc. Chem. Res. 31 1998 805
27. The surface representation was made inside program PyMOL, it is the solvent contact surface (not solvent accessible surface), which is traced out by the vdw surfaces of the water atoms when in contact with the protein.
28. For in vitro assay experimental procedures see: Brown, D. S.; Brown, G. R. WO 99/59959; Chem. Abstr. 1999, 131, 351089.
29. For further information on kinases and assay protocols, see: S.P. Davies, H. Reddy, M. Caivano, and P. Cohen Biochem. J. 351 2000 95 The kinase panel used was the Core panel shown in Table 1
30. Reich, S. H.; Bleckman, T. M.; Kephart, S. E.; Romines, W. H., III; Wallace, M. B. WO 01/53268; Chem. Abstr. 2001.